Publications by authors named "Perseghin G"
Aims: To compare medication persistence and efficacy of oral and subcutaneous semaglutide, in a real-world setting.
Materials And Methods: This is a single-center, retrospective observational cohort study. Patients with type 2 diabetes mellitus (T2DM) starting treatment with either formulation of semaglutide between January 1 2019 and July 31 2023 and with at least one follow-up visit were included.
Natriuretic peptides (NPs) are polypeptide hormones involved in the homeostasis of the cardiovascular system. They are produced by cardiomyocytes and regulate circulating blood volume and sodium concentration. Clinically, measurements of brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are recommended by international guidelines as evidence is accumulating on their usefulness.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the link between resting heart rates above 70 beats/minute in type 2 diabetes mellitus (T2D) patients and increased cardiovascular risk, aiming to determine if this reflects heightened sympathetic nervous system activity.
- Results indicate that higher heart rates were associated with greater muscle sympathetic nerve activity (MSNA) and norepinephrine levels, suggesting a significant relationship between heart rate and sympathetic overdrive in T2D patients.
- The findings highlight the importance of monitoring heart rates in T2D, as they may help identify patients with increased sympathetic activity, warranting further research into lifestyle and medication strategies that could potentially mitigate this risk.
Article Synopsis
- The review discusses the pharmacological treatment options for non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD), highlighting their link to obesity and type 2 diabetes.
- It outlines the challenges faced in clinical trials, such as issues with liver biopsies, patient recruitment, and variable placebo responses, while comparing regulatory requirements from the FDA and EMA.
- The study emphasizes the potential of repurposing existing diabetes and obesity medications and introduces drug candidates in Phase 3 trials, suggesting that combination therapies may enhance treatment effectiveness, especially in different disease stages.
Article Synopsis
- A recent consensus defined metabolic dysfunction associated steatotic liver disease (MASLD) and introduced MetALD, a new condition where steatotic liver disease, metabolic dysfunction, and moderate alcohol intake occur together.
- A systematic review and meta-analysis of 5 studies with nearly 10 million participants examined the links between MASLD and MetALD with serious health outcomes.
- Findings showed both conditions were linked to higher rates of all-cause mortality and cardiovascular disease, with MetALD presenting even greater risks, particularly for cancer-related and cardiovascular mortality.
Aims: To evaluate the impact of adherence to glucagon like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose transporter two inhibitors (SGLT2-I) on clinical outcomes and costs in patients with type 2 diabetes mellitus (T2DM).
Materials And Methods: The 121,115 residents of the Lombardy Region (Italy) aged ≥40 years newly treated with metformin during 2007-2015 were followed to identify those who started therapy with GLP1-RA or SGLT2-I. Adherence to drug therapy over the first year was defined as the proportion of days covered >80%.
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of glucose-lowering agents widely used for the treatment of type 2 diabetes mellitus. A number of clinical trials in type 2 diabetic patients with different degrees of renal impairment have clearly demonstrated that SGLT2 inhibitors reduce the progression rate of diabetic kidney disease. Furthermore, recent studies have shown that SGLT2 inhibitors also exert a protective effect in the case of non-diabetic kidney disease.
View Article and Find Full Text PDFContext: Patients with diabetes are at increased risk of dying from liver-related events, but little is known on whether this increased risk has changed in recent years.
Objective: The aim of the present study is to describe time trends in cause-specific liver-related mortality in people with and without diabetes from the general Italian population.
Methods: Data were retrieved from the health care utilization databases of Lombardy, a region of Italy that accounts for about 16% (almost 10 million) of its population.
Objective: The purpose of this study was to determine the effectiveness of a new AI-based tool called NAIF (NAFLD-AI-Fibrosis) in identifying individuals from the general population with advanced liver fibrosis (stage F3/F4). We compared NAIF's performance to two existing risk score calculators, aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 (Fib4).
Methods: To set up the algorithm for diagnosing severe liver fibrosis (defined as Fibroscan® values E ≥ 9.
Background & Aim: Liver fibrosis is the strongest predictor of liver-related mortality in many chronic liver diseases. NT-ProBNP is independently associated with cardiovascular mortality in general population settings. Here, we evaluate the relative contribution of non-invasively identified liver fibrosis and NT-ProBNP on all-cause and cardiovascular mortality in patients with metabolic (dysfunction)-associated steatotic liver disease (MASLD).
View Article and Find Full Text PDFArticle Synopsis
- A study identified insulin sensitivity (IS) in patients with type 2 diabetes (T2D) using common clinical parameters, aiming to link it with mortality risks.
- The model calculated IS from factors like triglycerides and body mass index, showing strong correlation with direct measurements of glucose disposal.
- Results indicated that higher IS was associated with lower all-cause and cardiovascular mortality, suggesting its clinical importance in managing T2D.
Background And Aims: Several studies reported an association between liver stiffness measurement (LSM) obtained through vibration-controlled transient elastography (VCTE) and all-cause mortality in patients with nonalcoholic fatty liver disease (NAFLD). The objective of this systematic review and meta-analysis was to summarize available evidence on the nature and magnitude of this association.
Methods: We systematically searched PubMed-MEDLINE and Scopus up to April 2023 for observational cohort studies in which LSM was measured with VCTE in patients with NAFLD or in general population settings, with a follow-up ≥1 year and with available data on all-cause mortality.
Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD) affects ~70% of patients with type 2 diabetes (T2D), with ~20% showing signs of advanced liver fibrosis. Patients with T2D are at an increased risk of developing cirrhosis, liver failure, and hepatocellular carcinoma and their liver-related mortality is doubled compared with non-diabetic individuals. Nonetheless, the condition is frequently overlooked and disease awareness is limited both among patients and among physicians.
View Article and Find Full Text PDFBackground And Objective: The aim of the present study is to explore the epidemiologic impact of the definition of steatotic liver disease (SLD) proposed by a multi-society (American Association for the Study of the Liver-the European Association for the Study of Liver Diseases-Asociación Latinoamericana para el Estudio del Hígado) Delphi consensus statement.
Methods: This is a cross-sectional study of US adults participating in the 2017-2020 cycles of the National Health and Nutrition Examination Survey who were evaluated by vibration-controlled transient elastography. Hepatic steatosis and fibrosis were diagnosed by the median value of controlled attenuation parameter and liver stiffness measurement using cut-offs of 274 dB/m and 8.
Sex hormones impact body composition. Data on the specific impact of each hormone on different body depots in men and women are scarce. The aim of this study is to evaluate the association between testosterone, estradiol and body fat distribution in the general population.
View Article and Find Full Text PDFThe cardioprotective effects of sodium glucose cotrasponter 2 (SGLT2) inhibitors seem to be independent from the effects on glycemic control, through little-known mechanisms. In this study, we investigate whether the cardioprotective effects of empagliflozin, a SGLT2 inhibitor, may be associated with myocardial sympathetic activity and inflammatory cell infiltration in an experimental model of angiotensin II-dependent hypertension. Angiotensin II (Ang II), Ang II plus Empagliflozin, physiological saline, or physiological saline plus empagliflozin were administered to Sprague Dawley rats for two weeks.
View Article and Find Full Text PDFAim: Identifying patients with fibrotic nonalcoholic steatohepatitis (NASH) is crucial in order to refer them to specialist care as fibrotic NASH represents one of the major inclusion criteria for clinical trials. The aim of this study is to report the prevalence of fibrotic NASH in the general US population across the spectrum of glucose tolerance and evaluate the performance of the recently proposed Fibrotic NASH Index (FNI).
Methods: This is a cross-sectional study of US adults participating in the 2017-2020 cycles of the National Health and Nutrition Examination Survey.
Introduction: Serum neurofilament light chain (sNfL) levels are biomarkers of neuro-axonal injury in multiple neurological diseases. Little is known on their potential role as prognostic markers in people without known neurological conditions.
Objective: The aim of this study is to evaluate the association between sNfL levels and all-cause mortality in a general population setting.
Background: To evaluate the protective effect of oral antidiabetic drugs in a large cohort of elderly patients with type 2 diabetes differing for age, clinical status, and life expectancy, including patients with multiple comorbidities and short survival.
Methods: A nested case-control study was carried out by including the cohort of 188,983 patients from Lombardy (Italy), aged ≥ 65 years, who received ≥ 3 consecutive prescriptions of antidiabetic agents (mostly metformin and other older conventional agents) during 2012. Cases were the 49,201 patients who died for any cause during follow-up (up to 2018).